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Serum albumin enhances the membrane activity
of ZnO nanoparticles†
Adam H. Churchman,a Rachel Wallace,b Steven J. Milne,b Andy P. Brown,b
Rik Brydsonb and Paul A. Beales*a
We investigate the eﬀect of serum albumin on the interaction of ZnO
nanoparticles with DOPC lipid membranes and show that the size-
stabilizing eﬀect of the protein corona enhances their interaction with
lipid membranes, which manifests, in part, as an increased ordering in
the lipid packing.
Formation of protein coronas around engineered nanoparticles
(NPs) has been shown to have a significant impact on how these
materials interact with biology.1 This has profound implications
for the potential toxicity of nanomaterials and their biomedical
applications such as therapeutic delivery and diagnostic imaging.2
For example, protein coronas formed in serum have been shown to
reduce cell uptake and toxicity of several classes of NP.3–6 However,
serum has been found not to reduce the toxicity of ZnO NPs to an
MCF-7 human breast cancer cell line.6 It is becoming clear that
understanding the eﬀect of serum proteins within toxicology assays
is an important challenge in resolving apparently contradictory
reports of nanomaterial toxicity.7
To gain a deeper fundamental understanding of the physical
nature of these nano–bio interactions, minimal model systems with
a small, known number of constituents need to be employed.8 Such
minimal systems oﬀer unique opportunities to isolate and investi-
gate passive interaction mechanisms. Of particular interest is the
ability of NPs to cross biological barriers, which in part determines
their eventual biodistribution. For example, the interaction of NPs
with plasma membranes regulates their access to the interior
biomolecular machinery of cells. The structural matrix of a cell
membrane consists of a lipid bilayer, which can be reconstituted
into model biomembranes in the form of unsupported vesicles for
the purpose of fundamental biophysical analysis. Interactions of
NPs with lipid membranes reveal rich phenomenology, even within
such minimal systems, where interactions are highly dependent
upon NP properties such as polarity, charge, shape and size.9,10
Here, we investigate the interaction of ZnO NPs with model
biomembranes composed of the common phospholipid dioleoyl
phosphocholine (DOPC). ZnO NPs are commonly used in coatings,
pigments and sun screens and despite its solubility is generally
shown not to be toxic unless inhaled.11,12 When however ZnO NPs
do penetrate cells it has recently been reported that they may be
carcinogenic as a result of causing DNA damage.13 Therefore work
towards understanding the interactions of ZnO NPs at the cell
membrane, which may allow them to gain access to the cell
interior, will be important in developing particle engineering
strategies that passivate these materials against cell uptake (or to
optimise uptake for therapeutic purposes, e.g. cancer therapy14,15).
To mimic the eﬀects of a primitive protein corona, our studies are
conducted with or without the presence of serum albumin (bovine;
BSA), by far the most abundant protein in blood serum. ZnO NP
samples prepared with BSA were created from an initial stock
solution of 10 mg ZnO NPs dispersed within 1 ml of 100 mg ml1
BSA in water. This concentration of BSA is comparable to the total
protein concentration in blood serum, approximately half of
which is serum albumin. This stock solution was diluted into
experimental samples as required.
We find that the presence of BSA significantly increases
morphological transitions of lipid membranes resulting from
addition of ZnO NPs. The primary membrane models we utilise
are giant unilamellar vesicles (GUVs), which allow direct optical
observation of membrane perturbation by NPs due to their
microscale architecture.16–19 DOPC GUVs were formed by electro-
formation20 and contained a trace component (0.5 mol%) of
Rhodamine-labelled lipid (Rh-DOPE). Confocal fluorescence micro-
scopy was used to image morphology changes in GUVs induced by
ZnO NPs. Control experiments confirmed no significant impact on
GUV morphology is caused by BSA alone or Zn2+ ions (5.6 mM
ZnSO4: equivalent to the maximum total Zn concentration in our
ZnO NP experiments). Fig. 1a shows GUVs in the presence of
420 mg ml1 ZnO NPs (no BSA); little change in morphology was
observed except for the occasional lipid tubule protruding from/
into some GUVs. Conversely when the same concentration of ZnO
NPs in the presence of 4.2 mg ml1 BSA is added to GUVs, several
significant morphological responses were seen (Fig. 1b–d).
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The overall interaction appears to be highly complex with aggrega-
tion of GUVs (Fig. 1b), large numbers of lipid nanotubes ejected
from the membrane (Fig. 1c) and fission processes into smaller
GUVs (Fig. 1d). Despite these dramatic observations, the perme-
ability barrier of the membrane surprisingly remains largely intact.
10 kDa Alexa Fluor 647 dextran (blue; A647-10k) acting as a passive
leakage marker in the external environment of the GUVs remains
excluded from the interior lumen of 495% of GUVs (Fig. 1). The
conservation of the membranes’ barrier properties strongly implies
that these NPs do not passively translocate into the interior lumen
of the GUVs and thus only directly interact with the outer lipid
monolayer of the GUVs. The resultant asymmetry of NPs across the
membrane may therefore lead to curvature eﬀects that drive the
observed morphological changes, similar to previous reports.16
In the absence of BSA, large darker regions were seen to increase
in the background of GUV images, which we interpret to be a
result of ZnO NP aggregation. This would likely deplete NPs in
the suspension, preventing significant interaction with GUV
membranes. We investigate the stability of ZnO NP aqueous disper-
sions with and without BSA by dynamic light scattering (DLS) and
transmission electron microscopy (TEM) (Fig. 2). TEM samples were
prepared by thin film plunge freezing before sublimation of vitrified
water under vacuum, preventing agglomeration of NPs due to
sample drying eﬀects.21 Large microscale clusters of ZnO NPs in
the absence of BSA are detected by both techniques. However the
nanoscale size distribution of ZnO NP dispersions is more stable in
the presence of BSA. The nanoscale size distribution is likely
preserved by adsorption of proteins onto the NP surface, which
lowers the surface free energy, preventing significant aggregation.
Evidence for the formation of a corona can be seen in Fig. 2d.
The edge of the ZnO NP cluster is encased by a 5–10 nm thick
low contrast, amorphous surface layer (assumed to be BSA) as
highlighted by the arrow; this is in contrast to the facetted, well
defined edges of ZnO NPs imaged after dispersion in water alone.
To better understand the impact of ZnO NPs on membrane
structure, we use the fluorescence probe Laurdan, which is sensitive
to packing and hydration of the lipid bilayer.22 Laurdan has two
emission maxima at 440 nm and 490 nm, where an increase in the
440 nm peak with respect to the 490 nm peak indicates that the
membrane is in a less hydrated, more ordered state. The change in
Laurdan fluorescence with time for an ensemble sample of large
unilamellar vesicles (LUVs) in the presence of ZnO NPs is shown in
Fig. 3. Clear diﬀerences occur between samples with and without
BSA. When BSA stabilizes ZnO NP dispersions, the 440 nm peak
increases significantly with respect to 490 nm spectral peak, indicat-
ing increased ordering of lipids in the membrane. However, without
BSA, the intensities at 440 nm and 490 nm both reduce fairly
concurrently implying no significant change in lipid ordering but
the decrease in overall intensity perhaps relates to adsorption of lipid
onto ZnO NP aggregates, removing some of the LUVs from the
sample.
The detected increase in lipid ordering in the presence of BSA-
stabilized ZnO NPs is confirmed by multiphoton fluorescence
imaging of GUVs containing Laurdan. The normalised ratiometric
intensity of the two emission maxima of Laurdan is known as the
generalised polarisation function, GP = (I440 I490)/(I440 + I490) where
Ix is the fluorescence intensity at x nm. Higher GP values imply a
more ordered, less hydrated lipid membrane. Multiphoton
Fig. 1 Confocal microscopy images of Rh-DOPE labelled GUVs (red) with passive
leakage marker A647-10k (blue) in the extravesicular solution. (a) 0.42 mg ml1
ZnO NPs (no BSA) has minimal impact on GUV morphology; (b–d) 0.42 mg ml1
ZnO NPs in 4.2 mg ml1 BSA causes (b) GUV aggregation, (c) ejection of lipid
tubules, (d) fission of GUVs shown by time series where GUV initially shrinks in
size before elongation and splitting into at least 3 daughter GUVs. Note that few
GUVs leak to A647-10k despite dramatic morphological eﬀects.
Fig. 2 (a) Particle size distributions by DLS and TEM for ZnO NPs with and without
the presence of BSA; (b–d) TEM images of (b) ZnO NPs (no BSA), (c) ZnO NPs (BSA),
(d) higher resolution image of ZnO NPs (BSA) showing evidence of a protein
corona, highlighted by the arrow. Scale bars are (b) 2 mm, (c) 0.5 mm and (d) 50 nm.
Fig. 3 Kinetic evolution of Laurdan spectra after addition of ZnO NP samples.
Spectra were taken every 2 min for 1 h. Samples contained 100 mM DOPC LUVs
with 0.5 mol% Laurdan in the membranes. (a) 120 mg ml1 ZnO NPs (no BSA);
(b) 120 mg ml1 ZnO NPs (1.2 mg ml1 BSA).
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microscopy allows determination of GP with sub-micron spatial
resolution.23 GP histograms derived from GUV images (Fig. 4) show
an increase in mean GP after 30 min incubation with BSA-stabilised
ZnO NPs, implying an increase in lipid ordering. A decrease in GP
distribution width is also seen, implying a narrower range of
configurations experienced by Laurdan probes. On average, samples
with 500 mg ml1 ZnO NPs and 5 mg ml1 BSA showed a shift in
mean GP value (DGP) of +0.12 0.03 and a decrease in distribution
width of 0.30  0.10. Neither Laurdan GP maps (Fig. 4a) nor
confocal images (Fig. 1) show evidence for phase separation of
domains of more ordered lipids within the lipid membranes on
optically resolvable length scales, consistent with previous reports of
NP-induced lipid ordering in membranes.17,24
In conclusion, we have shown that BSA stabilizes the nano-
scale size distribution of aqueous dispersions of ZnO NPs and
that this significantly increases their membrane activity.
While the interaction is clearly complex with several diﬀerent
morphology changes observed, we show that these NPs induce
an increased ordering of lipids consistent with maintenance
of the membrane permeability barrier during the various
morphological transitions. This in turn suggests that ZnO
NPs do not cross the membrane (as has been reported for
MCF-7 cells6) and so an asymmetry of NPs across the lipid
bilayer is a likely mechanism that gives rise to curvature driven
morphology changes. The smaller size of BSA-ZnO NPs will also
create a larger total contact area between NPs and the membrane
leading to a greater net impact onmembrane properties.25 Ordering,
condensation and solidification of lipidmembranes are emerging as
common themes in NP–biomembrane interactions.17,24 Further
work is required to determine if there is a direct link between the
ordering of lipids by NPs and the well established eﬃcacy of NPs to
cross plasma membranes and access the cell’s interior workings. It
will also be necessary to improve our understanding of the coupling
between particle type, protein corona structure (e.g. exposed
functional groups) and the interaction with model biomembranes.
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